Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Nasopharyngeal Carcinoma 1Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1

Interventions

toripalimab 5Cisplatin 5pembrolizumab 3Radiotherapy, Intensity-Modulated 3Heavy Ion Radiotherapy 3Gemcitabine 3anlotinib 2spartalizumab 1nedaplatin 1icotinib 1fludarabine phosphate 1fludarabine 1famitinib 1donafenib 1Vorinostat 1TP protocol 1Sodium Chloride 1SHR-1701 1Quality of Life 1Paclitaxel 1N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 1Interleukin-2 1Immunotherapy, Adoptive 1Gefitinib 1Cyclophosphamide 1Cetuximab 1Celecoxib 1Bevacizumab 1Adjuvants, Pharmaceutic 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Nasopharyngeal Carcinoma × icotinib × Clear all
NCT01534585 2018-04-17

Safety and Efficacy Study of Icotinib With Intensity-modulated Radiotherapy in Nasopharyngeal Carcinoma

Taizhou Hospital

Phase 1/2 Completed
48 enrolled
Head & Neck

Nasopharyngeal Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡